How Physicians Can Detect ctDNA in Melanoma

March 17, 2020

David Polsky, MD, PhD, discusses methods to identify circulating tumor DNA in patients with melanoma.

Death By Cancer Shows Decline in the 2020 Annual Report to the Nation on the Status of Cancer

March 17, 2020

From 2001 to 2017, the cancer death rates continued to decline in the United States, and these decreases were observed in all major racial and ethnic groups, as well as in males, females, adolescents, young adults, and children. However, the rates of cancer incidence for all cancers slightly increased in females from 2012 to 2016, according to the Annual Report to the Nation on the Status of Cancer, which was published in Cancer.

Adjuvant T-VEC Is Superior to Surgery Alone in Melanoma

February 26, 2020

Adjuvant treatment with talimogene laherparepvec in patients with resectable advanced melanoma demonstrated better recurrence-free survival and overall survival compared with surgery alone, according to results of a study presented at a poster session at the 16th International Congress of the Society for Melanoma Research.

The Rationale for the Administering the Seviprotimut-L Vaccine to Patients with Melanoma

February 21, 2020

Craig L. Slingluff, MD, explains the rationale behind part B1 of the MAVIS study , which is investigating the use of the Seviprotimut-L vaccine in melanoma.

Liquid Biopsy May Predict Relapse Risk and Aid Therapy Decision-Making in Node-Positive Melanoma

February 06, 2020

Performing a liquid biopsy of circulating tumor cells may help identify patients who are at risk for node-positive melanoma relapse and identify patients who wish to avoid the toxicities associated with systemic adjuvant therapy, according to the results of a prospective study from The University of Texas MD Anderson Cancer Center, which was recently published in Clinical Cancer Research.

Comparing Toxicity Profiles of Immunotherapy Versus BRAF-Targeted Therapy in Melanoma

January 29, 2020

Ryan J. Sullivan, MD, compares the toxicity profiles of BRAF-targeted therapy and immunotherapy used for the treatment of patients with melanoma.

Triplet Regimen Induces Clinical Benefit at 24-Month Follow-Up in BRAF-Mutant Melanoma

January 21, 2020

In an interview with Targeted Oncology, Pier Francesco Ferrucci, MD, discussed the findings from the updated analysis, which he shared in a presentation at the 16th International Congress of the Society for Melanoma Research, highlightening the important takeaways from this follow-up analysis.

Exploring Treatment Options for Patients With Advanced Melanoma

January 09, 2020

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the current treatment options that are approved around the world for patients with advanced melanoma. These treatments include both immunotherapies, such as immune checkpoint inhibitors, and targeted therapies.

IMspire150 Study Meets Primary Endpoint of PFS in Patients With Melanoma

December 13, 2019

The combination of atezolizumab, cobimetinib, and vemurafenib reduced the risk of disease progression or death compared with placebo in patients with BRAF V600 mutation-positive advanced melanoma, meeting the primary endpoint of progression-free survival in the phase III IMspire150 study, according to a press release from Roche.

2020 Meeting on Cutaneous Malignancies Will Address Next Steps For Immunotherapy

December 03, 2019

Treatment with immunotherapy has become ingrained in the standard of care for treating patients with melanoma, but investigators continue to research new combinations and treatment strategies that can improve patients outcomes. One approach that has generated a great deal of interest and is a significant focus of ongoing trials involves adjuvant and neoadjuvant therapy, according to Jeffrey S. Weber, MD, PhD.